Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The study is designed to measure the efficacy and safety of levetiracetam on levodopa-induced
dyskinesias in late-stage Parkinson's disease. The patients are planned to be treated with
levetiracetam (up to 2000 mg per day) or placebo for 13 weeks. Efficacy measure is the
modified AIMS.